Today: 13 June 2026
Browse Category

SWX:UBXN 6 June 2025

Everything You Never Knew You Needed to Know About Differential and Precise Point Positioning

Everything You Never Knew You Needed to Know About Differential and Precise Point Positioning

RTK delivers centimeter-level accuracy in real time when the base is within 10–20 km, while PPP provides similar accuracy globally but requires minutes to converge. John Deere’s StarFire system improved from 10 cm to 5 cm accuracy using dual-frequency GPS+GLONASS. Galileo HAS began global decimeter-level PPP corrections in 2023. The u-blox ZED-F9P module enables centimeter-level positioning for drones and robots at low cost.

Stock Market Today

  • Rezolve AI Plans $300 Million Buyback Amid Valuation Debate
    June 12, 2026, 6:08 PM EDT. Rezolve AI (RZLV) is under the spotlight after announcing a US$300 million share buyback funded from cash reserves. Trading at US$2.53, the stock gained 5.86% in one day but shows a 9.96% decline over 30 days. The company reaffirmed its 2026 revenue guidance and appointed a new Chief Marketing Officer, signaling confidence in growth. A popular market narrative values the stock at US$10.00, suggesting significant undervaluation, driven by potential recurring revenue growth and improved margins. However, risks around ambitious revenue targets and vendor integrations persist. Contrarily, some models, like Simply Wall St's discounted cash flow analysis, value the stock as low as US$0.15. Investors face a wide valuation gap, weighing Rezolve AI's future growth prospects against execution risks.

Latest articles

Alumis Shares Surge 16% as Traders Eye New Drug Move

Alumis Shares Surge 16% as Traders Eye New Drug Move

12 June 2026
Alumis soared 15.55% to $24.15 on double average volume after strong analyst support and late-stage psoriasis data, but remains a high-risk, loss-making biotech with no approved products; key investor focus is on Phase 2b lupus data due Q3 and a planned psoriasis NDA filing in Q4, with future stock moves hinging on these clinical and regulatory milestones.
Go toTop